Research Article

Keywords: gastric cancer, preoperative chemo-radiotherapy, postoperative chemo-radiotherapy, long-term outcome

DOI: https://doi.org/10.21203/rs.3.rs-644806/v1

License: © 本工作根据创用CC4.0国际许可证授权。 Read Full License
Abstract

Background: peri-operative chemo-radiotherapy played important role in locally advanced gastric cancer. Whether preoperative strategy can improve the long-term prognosis compared with postoperative treatment is unclear. The study purpose to compare long-term oncologic outcomes in locally advanced gastric cancer patients treated with preoperative chemo-radiotherapy (pre-CRT) and postoperative chemo-radiotherapy (post-CRT).

Methods: From January 2009 to April 2019, 222 patients from 2 centers with stage T3/4 and/or N positive gastric cancer who received pre-CRT and post-CRT were included. After propensity score matching (PSM), comparisons of local regional control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS) and overall survival (OS) were performed using Kaplan-Meier analysis and log-rank test between pre- and post-CRT groups.

Results: The median follow-up period was 30 months. 120 matched cases were generated for analysis. Three-year LC, DMFS, DFS and OS for pre- vs. post-CRT groups were 93.8% vs. 97.2% (p=0.244), 78.7% vs. 65.7% (p=0.017), 74.9% vs. 65.3% (p=0.042) and 74.4% vs. 61.2% (p=0.055), respectively. Pre-CRT were significantly associated with DFS in uni- and multi-variate analysis.

Conclusion: Preoperative CRT showed advantages of long-term outcome compared with postoperative CRT.

Trial registration: ClinicalTrial.gov NCT01291407, NCT03427684 and NCT04062058, date of registration: Feb 8, 2011

Background

In China, 6.791 million new cases and 498 thousand deaths of gastric cancer every year, and 70.8% of newly diagnosed patients were locally advanced stage[1, 2]. The crucial role of peri-operative chemo-radiotherapy in locally advanced gastric cancer have been concluded by studies[3–9]. Postoperative radiotherapy based on pathological stages, while preoperative radiotherapy has the advantages of down staging and lower rate of severe adverse events.

However, whether preoperative strategy could improve the prognosis compared with postoperative treatment is unclear[10, 11]. The purpose of this study was to compare long-term outcomes in locally advanced gastric cancer patients after preoperative chemo-radiotherapy (pre-CRT) and postoperative chemo-radiotherapy (post-CRT).

Methods

Patients and eligibility

From January 2009 to April 2019, patients from 2 centers with locally advanced gastric adeno-carcinoma who received pre-CRT or post-CRT were included. The inclusion criteria were as follows: 18–75 years old, male or female; stage T3–4 and/or N + gastric cancer without distant metastasis; Karnofsky score ≥ 70; normal haematology examination. For pre-CRT patients, radiological examinations, including CT, MRI with or without...
PETCT, and gastroscopy should be performed for clinical TNM stage and pathology diagnosis. For post-CRT patients, pathology stage should be confirmed by post-operative histo-pathological results. All patients signed informed consent forms.

Treatment regimens

Pre-CRT patients were initially treated with radiotherapy concurrent with S-1. Three weeks after radiotherapy, patients were given neo-adjuvant chemotherapy with oxaliplatin and S-1 (SOX). Pre-operative imaging evaluation was performed 21 days after neo-adjuvant treatment. The surgical procedures were determined based on multidisciplinary team (MDT) discussion. Inoperable patients continued with 3 cycles of chemotherapy, and the chemotherapy regimen was not specified. The patients in post-CRT group received radiotherapy concurrent chemotherapy, which with S-1 or capecitabine regimen, after radical resection. D2 resection and adjuvant chemotherapy was recommended for entire cohort. And pre- or post-operative radiotherapy dose was prescribed as 45Gy, with intensity modulated radiotherapy (IMRT) or volumetric modulated arc radiotherapy (VMAT) technique.

Evaluation and endpoints

The preoperative TNM stage was evaluated via gastric MRI, gastroscopy, endoscopic ultrasonography and CT images of thoracic, abdominal and pelvic. Diagnostic laparoscopy and PETCT scans were not mandatory. Surgical resection specimens were subjected to an extensive evaluation of primary lesions and lymph nodes.

Follow-up was scheduled at 3-month intervals for the first 2 years and then at 6-month intervals until 5 years. Diagnostic evaluations were performed using CT of the chest and abdomen and MRI or gastroscopy only if necessary. The primary endpoint was disease-free survival (DFS), defined as the interval from the date of the surgery for post-CRT group or the first pre-CRT to the date of recurrence or death from any cause. The secondary endpoints were overall survival (OS), local control (LC) and distant metastasis free survival (DMFS).

Statistical analysis

Since patients were not randomly assigned to either treatment group due to the retrospective nature of the analysis, propensity score matching (PSM) was used to determine the independent impact of treatment modality on long-term oncologic outcomes. First, logistic regression using these variables was performed to obtain the propensity score for each patient (defined as the probability to be assigned to pre- or post-CRT group according to the individual profile of these covariates). Then, patients in each group were matched according to the calculated propensity scores using a k nearest neighbours (KNN) algorithm with a threshold of \( c \leq 0.05 \). After matching, Kaplan-Meier analysis for LC, DMFS, DFS and OS were performed and compared between two groups using log-rank test.

Statistical analysis was performed by the SPSS Version 22 software (IBM Corporation, Armonk, NY, USA). A two-sided p-value of < 0.05 was considered significant.

The Kaplan-Meier method was used to analyse the survival rate using R software (R Foundation for Statistical Computing, Vienna, Austria).
Results

Clinical characteristics

Two hundred and twenty two patients were enrolled, and the follow-up rate was 100%. In total, 79.3% were male patients. The median age was 60 (27–75) years. 89.6% and 84.2% of patients was T3/4 lesions and clinical N positive, respectively. Table 1 summarizes the patients’ baseline characteristics for each group, indicating relevant differences between the two. Patients in pre-CRT group significantly had a greater frequency of proximal segment gastric cancer, poorly differentiated pathological type, clinical T3/4 and N1/2 gastric cancer than in post-CRT group.

In pre-CRT group, the median duration between neo-adjuvant treatment and surgery was 52 (14–174) days. Twenty-two patients (23.9%) did not undergo a further surgical procedure because of disease progression or other personal reasons. Among these patients, 17 had distant metastasis (4 peritoneal, 4 liver, 2 para-aortic lymph nodes, 2 ovarian and 1 lung metastasis, and 5 unknown), 5 abandoned the operation due to personal reasons or other unknown reasons. Among the 70 resected patients, the rate of downstaging, ypN0 and pathologic complete response (pCR) rate was 64.1% (n = 59), 50.0% (n = 46) and 15.2% (n = 14) respectively. In post-CRT group, 119 patients (91.5%) underwent adjuvant chemotherapy, which was more than 81.5% in pre-CRT group.
|                          | Total          | Entire cohort | PSM cohort      |          |          |          |          |
|--------------------------|----------------|---------------|-----------------|----------|----------|----------|----------|
|                          | (n=222, %)     | pre-CRT (n=92, %) | post-CRT (n=130, %) | p        | pre-CRT (n=60, %) | post-CRT (n=60, %) | p        |
| Sex                      |                |                |                 |          |          |          |          |
| Male                     | 169 (76.1)     | 73 (79.3)      | 96 (73.8)       | 0.344    | 48 (80.0) | 47 (78.3) | 0.822    |
| Female                   | 53 (23.9)      | 19 (20.7)      | 34 (26.2)       |          | 12 (20.0) | 13 (21.7) |          |
| Median age               | 60 (27-75)     | 61 (35-75)     | 59 (27-75)      | 0.657    | 60 (35-75) | 60 (31-75) | 0.817    |
| Segment                  |                |                |                 |          |          |          |          |
| Proximal                 | 87 (39.2)      | 57 (62.0)      | 30 (23.1)       | 0.000    | 31 (51.7) | 25 (41.7) | 0.171    |
| Body                     | 54 (24.3)      | 12 (13.0)      | 42 (32.3)       |          | 11 (18.3) | 20 (33.3) |          |
| Distal                   | 81 (36.5)      | 23 (25.0)      | 58 (44.6)       |          | 18 (30.0) | 15 (25.0) |          |
| Pathological type        |                |                |                 | 0.103    |          |          |          |
| Well differentiated      | 1 (0.4)        | 1 (1.1)        | 0 (0.0)         | 0.000    | 0 (0.0)  | 0 (0.0)  |          |
| Moderate differentiated   | 60 (27.0)      | 14 (15.2)      | 46 (35.4)       |          | 14 (23.3) | 19 (31.7) |          |
| Poorly differentiated     | 124 (55.9)     | 67 (72.8)      | 57 (43.8)       |          | 41 (68.3) | 31 (51.7) |          |
| Mucinous adenocarcinoma  | 12 (5.4)       | 2 (2.2)        | 10 (7.7)        |          | 2 (0.3)  | 5 (8.3)  |          |
| Signet ring cell carcinoma | 20 (9.0)   | 7 (7.6)        | 13 (10.0)       |          | 3 (0.5)  | 5 (8.3)  |          |
| Unknown                  | 5 (2.3)        | 1 (1.1)        | 4 (3.1)         |          | 0 (0.0)  | 0 (0.0)  |          |
| T stage*                 |                |                |                 | 0.000    |          | 0.691    |          |
| T1                       | 4 (1.8)        | 0 (0.0)        | 4 (3.1)         |          | 0 (0.0)  | 0 (0.0)  |          |
| T2                       | 19 (8.6)       | 2 (2.2)        | 17 (13.1)       |          | 2 (3.3)  | 4 (6.7)  |          |
| T3                       | 106 (47.7)     | 37 (40.2)      | 69 (53.1)       |          | 29 (48.3) | 29 (48.3) |          |
| T4                       | 93 (41.9)      | 53 (57.6)      | 40 (30.8)       |          | 29 (48.3) | 27 (45.0) |          |
| N stage*                 |                |                |                 |          | 0.068    |          |          |
| N0                       | 35 (15.8)      | 11 (11.6)      | 24 (18.5)       | 0.000    | 10 (16.7) | 12 (20.0) |          |
| N1                       | 49 (22.0)      | 27 (29.3)      | 22 (16.9)       |          | 17 (28.3) | 12 (20.0) |          |
| N2                       | 65 (29.3)      | 36 (39.1)      | 29 (22.3)       |          | 21 (35.0) | 12 (20.0) |          |
N3 | 73 (32.9) | 18 (19.6) | 55 (42.3) | 12 (20.0) | 24 (40.0)  
Surgical procedure  
D1 | 35 (15.8) | 9 (9.8) | 26 (20.0) | 0.000 | 9 (15.0) | 12 (20.0) | 0.332  
D1+ | 47 (21.2) | 17 (18.5) | 30 (23.1) | 12 (20.0) | 17 (28.3)  
D2 | 118 (53.1) | 44 (47.8) | 74 (56.9) | 39 (65.0) | 31 (51.7)  
No operation | 22 (9.9) | 22 (23.9) | -  
Peri-operative chemo.  
Yes | 194 (87.7) | 75 (81.5) | 119 (91.5) | 0.049 | 55 (91.7) | 56 (93.3) | 0.841  
No | 28 (12.6) | 17 (18.5) | 11 (8.5) | 5 (8.3) | 4 (6.7)  
*T and N stage of pre-CRT group were clinical staging.  
Entire cohort prior to propensity score matching  
The median follow-up for survivors was 30 (range: 8–84) months in pre-CRT group and 39 (range: 6–90) months in post-CRT group, respectively. There were no significant differences in clinical outcomes between the two groups before PSM analysis (Table 2 and Fig. 1).  

| Long-term outcome of pre- and post-CRT Group before and after PSM  
|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                     | Entire cohort       |                     | PSM cohort          |                     |                     |                     |                     |                     |                     |
|                     | (n = 222)           |                     | (n = 120)           |                     |                     |
|                     | Pre-CRT | Post-CRT | p       | Pre-CRT | Post-CRT | p       |
| 3-year LC           | 90.6%     | 95.6%     | 0.056   | 93.8%     | 97.2%     | 0.244 |
| 3-year DMFS         | 59.6%     | 65.7%     | 0.922   | 78.7%     | 65.7%     | 0.017 |
| 3-year DFS          | 56.3%     | 61.2%     | 0.998   | 74.9%     | 65.3%     | 0.042 |
| 3-year OS           | 62.4%     | 64.5%     | 0.668   | 74.4%     | 61.2%     | 0.055 |

Table 3 presents the results of uni- and multi-variate Cox proportional hazards models for DFS. Clinical T/N stage and surgical procedure were associated with DFS in the univariate analysis and were included in the multivariate model. By multivariate analysis, surgical procedure was associated with improved DFS (p = 0.001).
| Variable                      | Entire cohort |            | PSM cohort |            |
|-------------------------------|---------------|------------|------------|------------|
|                               | Events/total  | HR (95%CI) | p          | HR (95%CI) | p          |
|                               | 81/222        |            |            | 36/120     |            |
|                               |               | p          |            | p          |
| **Univariate**                |               |            |            |            |
| **Sex**                       |               | 0.240      | 0.147      |            |
| Male                          | 1.335 (0.832-2.140) | 1.024 (0.465-2.253) |
| Female                        | 1             | 1          |            | 1          |
| **Segment**                   |               | 0.975      | 0.422      |            |
| Proximal                      | 1             | 1          |            | 1          |
| **Body**                      |               | 0.990(0.840-1.167) | 0.840(0.559-1.263) |
| **Distal**                    |               | 0.951(0.723-1.098) | 0.845(0.650-1.099) |
| **Pathological type**         |               | 0.123      | 0.373      |            |
| Well differentiated           | 1             |            |            |            |
| Moderate differentiated       | 1.000(0.561-1.652) | 1          |
| Poorly differentiated         | 1.001(0.652-1.623) | 1.465(0.933-2.302) |
| Mucinous adenocarcinoma       | 1.986(0.968-3.632) | 1.235(0.873-1.748) |
| Signet ring cell carcinoma    | 1.020(0.862-1.774) | 1.149(0.686-1.603) |
| **T stage**                   |               | 0.046      | 0.508      |            |
| T1                            |               |            |            |            |
| T2                            | 1.057(0.656-1.703) | 1          |
| T3                            | 1.184(0.783-1.805) | 1.489(0.430-6.744) |
| T4                            | 1.357(0.856-2.013) | 1.815(0.657-5.017) |
| **N stage**                   |               | 0.002      | 0.022      |            |
| N0                            | 1             |            |            |            |
| N1                            | 1.170(0.505-2.710) | 1.186(0.672-2.092) |
| N2                            | 1.234(0.778-1.655) | 1.279(0.781-2.181) |
| N3                            | 1.338(1.061-1.689) | 1.307(0.962-1.777) |
| **Surgical procedure**        |               | 0.001      | 0.788      |            |
| D1                            | 1.230(0.685-2.207) | 1.423(0.532-3.805) |
| D1+     | 1.091(0.569-2.091) | 1.119(0.524-2.392) |
|---------|--------------------|--------------------|
| D2      | 1                  | 1                  |
| No operation | 1.213(1.106-1.331) | -                  |
| Peri-operative chemo. | 0.988 | 0.369 |
| Yes     | 1                  | 1                  |
| No      | 1.005(0.630-1.807) | 1.202(0.754-2.244) |
| CRT timing | 0.998 | 0.042 |
| Pre-    | 1                  | 1                  |
| Post-   | 1.000(0.636-1.575) | 2.127(1.010-4.420) |

**Multivariate**

| T stage | 0.223 |
|---------|-------|
| T1      | 1     |
| T2      | 1.149(0.712-1.889) |
| T3      | 1.184(0.783-1.905) |
| T4      | 1.151(0.479-1.439) |

| N stage | 0.336 | 0.578 |
|---------|-------|-------|
| N0      | 1     | 1     |
| N1      | 1.772(0.946-1.812) | 1.379(0.661-3.370) |
| N2      | 2.059(1.039-2.211) | 1.648(0.872-4.549) |
| N3      | 2.565(1.526-2.699) | 1.307(0.806-7.008) |

| Surgical procedure | 0.001 |
|--------------------|-------|
| D1                | 1.520(0.997-3.237) |
| D1+               | 1.290(1.047-1.446) |
| D2                | 1     |
| No operation      | 2.213(0.881-5.440) |

| CRT timing | 0.038 |
|------------|-------|
| Pre-       | 1     |
| Post-      | 2.114(1.291-8.140) |

Propensity score-matched cohort

Propensity score matching resulted in 60 matched pairs (pre:- post-CRT = 1:1), for a total of 120 patients. Patient and tumour characteristics were not significantly different between two groups of matched pairs (Table 1), indicating that the matching procedure worked well. After PSM, the Pre-CRT group patients resulted in superior 3-
year DFS (74.9% vs. 65.3%, p = 0.042; Figure 2) and DMFS rate (78.7% vs. 65.7%, p = 0.017) to those in post-CRT group. The pre-CRT group showed a better 3-year OS trend (74.4% vs. 61.2%, p = 0.055) as compared with post-CRT group. No LC difference between these two groups was observed (93.8% vs. 97.2%, p = 0.244) (Table 2).

Clinical N stage and pre-CRT were significantly associated with DFS in the univariate analysis. And pre-CRT remained significant in the multivariate model (p = 0.038) (Table 2) in PSM cohort.
| Study         | Randomization design | Inclusion criteria                                      | OS of RT group | DFS of RT group | Comments                      |
|--------------|----------------------|--------------------------------------------------------|----------------|----------------|-------------------------------|
| Pre-CRT CAMS/PUMC[8] RT+S vs. S | Local advanced gastric cancer. | 5y-OS 30.1% 10y-OS 20.26% | - | Proportion of D2 resection: 40% |
| PRE-CRT CROSS[12] CRT+S vs. S | Oesophageal or junctional cancer; T1–3N0–1M0(UICC 6th edition). | 1y-OS 81% 2y-OS 67% 3y-OS 58% 5y-OS 47% | 1y-PFS 71% 2y-PFS 60% 3y-PFS 51% 5y-PFS 44% | Proportion of EGJ 22-26% |
| PRE-CRT POET[13] CT+CRT+S vs. CT+S | Adenocarcinoma of EGJ; T3-T4(UICC 5th edition). | 3y-OS 46.7% 5y-OS 39.5% | - | - |
| Post-CRT INT-0116[15] S+CRT vs. S | Adenocarcinoma of the stomach or EGJ; IB~IVM0. | 3y-OS 50% 3y-RFS 48% | Proportion of D2, D1, D0 resection: 10%, 36%, 54%; Proportion of EGJ 7.0% |
| Post-CRT ARTIST[17] S+XP+CRT+XP vs. S+XP | Gastric cancer; IB-IV(M0) (AJCC 6th edition); D2 resection. | 5y-OS 75% 3y-DFS 78% | - | - |
| Post-CRT CALGB 80101[22] S+CT+CRT+CT ECF vs. FU/LV CRT with FU | Gastric cancer /EGJ; IB-IV(M0) (AJCC 6th edition). | 5y-OS 44% 5y-DFS 37% vs. 39% (FU/ LV: ECF) | Proportion of EGJ 22% |
| Post-CRT CRITICS[23] ECC+S+ECC ECC+S+CRT | Gastric cancer/EGJ; IB-IVa (AJCC 6th edition). | 5y-OS 42% | 5-year EFS 38% | Proportion of D2+D3 <10%; Proportion of EGJ 17.1% |
| Post-CRT ARTIST II[24] S+CRT S+S1 | Gastric cancer; Stage II-III; | - | 3y-DFS 73% | - |


**Discussion**

The optimal strategy for locally advanced gastric cancer is peri-operative comprehensive treatment, including peri-operative chemotherapy, radiotherapy and novel molecular agents. To our knowledge, few studies have explored to compare the long-term outcomes of preoperative with postoperative chemo-radiotherapy in gastric cancer with PSM method. The survival analysis after PSM indicated that DFS rate of pre-CRT group was significant higher than that of post-CRT. And the pre-CRT group showed a trend towards to better 3-year OS.

Radiotherapy plays an important role in the comprehensive treatment of locally advanced gastric cancer. Seyedin et al analyzed the prognosis of 21472 patients with stage I-IV gastric cancer in SEER database. For patients with stage II, III, or IV, those treated with radiotherapy had the best outcome compared with the other treatment modalities[12]. The study based on 21447 cases of gastric cancer from the NCDB database showed that the use of RT in addition to chemotherapy was associated with a significant OS advantage[13]. In randomized studies of postoperative radiotherapy, although the series of ARTIST studies did not obtain positive results, INT0116 and CRITICS studies suggested that postoperative radiotherapy was effective for patients with specific treatment modality and disease stage[14–17]. Published clinical studies concerning neo-adjuvant treatment showed that preoperative CRT could improve the pCR rate and long-term outcomes[9]. The phase 3 randomized controlled study from our centre compared the prognosis of preoperative radiotherapy with that of surgery alone. The 5- and 10-year OS rates in the preoperative radiotherapy cohort were significantly better[8]. The CROSS study conducted similar results[18]. And our previous study reported the prognosis of preoperative CRT compared with that of preoperative chemotherapy. The 2-year DFS and LRFS rates of CRT group were better than preoperative chemotherapy [19]. Therefore, both the analysis based on big data and prospective randomized studies confirmed the value of radiotherapy. And radiotherapy is recommended as standard treatment for local advanced gastric cancer in NCCN and ESMO guidelines.

Local advanced gastric cancer is eligible for either pre- or post-operative CRT. However, at present, there is no large sample prospective randomized controlled study comparing these two strategies. In some pooled analysis studies, which compared pre- with post-CRT, results were inconsistent. Wong reviewed 16 randomized controlled studies, 3 meta-analyses and 1 practice guideline of preoperative CRT and postoperative CRT for gastric cancer[20]. They concluded that preoperative CRT is a very promising treatment strategy for local advanced gastric cancer. However, the results from SEER database study showed that for stage II patients the death hazard risk of treatment with adjuvant radiotherapy was the lowest. For patients with stage III-IV, there was no significant difference in death hazard risk between the pre- or post-operative radiotherapy strategy[12]. In the Afsaneh study, the results were similar. Twenty-one thousand four hundred and forty-seven cases of gastric cancer included in the NCDB database were divided into three groups: perioperative chemotherapy + operation group, perioperative chemotherapy + operation + adjuvant radiotherapy group and neo-adjuvant radiotherapy + operation + chemotherapy group. The results showed that the overall survival rate of the adjuvant radiotherapy group was the best (P < 0.001)[21]. Our study compared the long-term prognosis of pre- and post-operative
radiotherapy patients with PSM statistical method, which could minimize the selection bias between two groups. The results confirmed that preoperative radiotherapy had more advantages in the long-term prognosis.

The advantages of the preoperative treatment of gastric cancer include an improved R0 resection rate by downstaging, tolerable toxicities and a good long-term prognosis. However, the accuracy of the preoperative clinical staging of gastric cancer, especially the diagnosis of peritoneal metastasis, is challenging the clinical practice. In studies reported by surgeons, the incidence of intra-operative observed peritoneal metastasis could be as high as 30% in imaging diagnosed clinical M0 stage patients\[22\]. Patients with underestimated staging will progress during preoperative radiotherapy. Therefore, underestimating the clinical stage might be major issue, which may affect the overall prognosis of preoperative treatment modality. In the uni- and multi-variate factor analysis of our study, we found that the surgery was a good prognostic factor for long-term outcomes. And the main reason that patients did not receive surgery was disease progression, most likely caused by the underestimation of staging. After PSM, these patients without operation in pre-CRT group due to paired un-matching was excluded for further survival analysis. This might be the main cause of better DFS in pre-CRT group. Therefore, the accuracy of clinical staging before initial treatment is very important in the subsequent randomized controlled study and clinical practice.

In recent years, total neoadjuvant treatment has become a topic of high interest in the treatment of GI cancer, which can lead to downstaging and pCR\[23\]. The expected greater opportunity for delivering high-dose chemotherapy in the preoperative setting could theoretically improve the rate of R0 resection of the cancer, and thus increase relapse-free survival. This hypotheses was demonstrated in Stahl’s study. In this study, compared with preoperative chemotherapy, higher pCR, ypN0 and better OS tendency was achieved by chemo-radiotherapy, although the study recruited only 126 patients due to a slow recruiting speed.

There were some limitations in this study. First, the chemotherapy regimen and cycles were not detailed enough to evaluate the perioperative chemotherapy intensity of all patients, which might have influenced the long-term prognosis. Second, gastric cancer is highly heterogeneous. There were limited clinical and pathological factors that might be related to prognosis that were analysed in this study. Third, although the data come from two centers, the sample size was still not large enough, which might lead to biased results.

In conclusion, preoperative chemo-radiotherapy may have better long-term outcomes for locally advanced gastric cancer, compared with post-operative chemo-radiotherapy. Despite these encouraging results, further prospective randomized studies should be conducted.

**Abbreviations**

chemo-radiotherapy (pre-CRT)

postoperative chemo-radiotherapy (post-CRT)

multidisciplinary team (MDT)

intensity modulated radiotherapy (IMRT)

volumetric modulated arc radiotherapy (VMAT)
disease-free survival (DFS)
overall survival (OS)
local control (LC)
distant metastasis free survival (DMFS).
propensity score matching (PSM)
k nearest neighbours (KNN)
pathologic complete response (pCR)

Declarations

Declaration of interests

-Ethics approval and consent to participate

This study was approved by the ethics committee of Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CH-GI-121). All subjects signed a written informed consent form.

-Consent to publish

Not applicable.

-Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

-Competing interests

The authors declare that they have no competing interests.

-Funding

This work was supported by grants from the Natural Science Foundation of China (81773241 and 81871509) and the Central Public-interest Scientific Institution Basal Research Fund of the Chinese Academy of Medical Sciences (2018RC310010). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

-Authors’ Contributions

Study design: JJ and LN. Analyzed data or performed statistical analysis: LN. Drafted manuscript: LN. Reviewed and commented on the manuscript: LN, XX, ZD, WX, TY, CY, YL, JL, JJ, SJ, LW, FH, CB, LN, JH, QS, WS, LY, SY, LY, ZL and JJ. All authors read and approved the final manuscript.
References

1. Miao R, Li Z, Wu A: Data report of China Gastrointestinal Cancer Surgery Union (2014-2016). Chinese Journal of Practical Surgery 2018, 38(1):4.

2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J: Cancer statistics in China, 2015. CA Cancer J Clin 2016, 66(2):115-132.

3. Akce M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF: Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. J Gastrointest Oncol 2019, 10(1):85-94.

4. Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascini S, Fugazzola P, Tomasoni M, Glehen O, Catena F et al: Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg 2018, 51:120-127.

5. Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ et al: Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015, 16(9):1090-1098.

6. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27(6):851-856.

7. Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA et al: A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016, 27(4):660-667.

8. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)–report on 370 patients. Int J Radiat Oncol Biol Phys 1998, 42(5):929-934.

9. Meng X, Wang L, Zhao Y, Zhu B, Sun T, Zhang T, Gu X, Zheng Z: Neoadjuvant Chemoradiation Treatment for Resectable Esophago-Gastric Cancer: A Systematic Review and Meta-Analysis. J Cancer 2019, 10(1):192-204.

10. Xue K, Ying X, Bu Z, Wu A, Li Z, Tang L, Zhang L, Zhang Y, Li Z, Ji J: Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial. Chin J Cancer Res 2018, 30(5):516-525.
11. Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y et al: Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). *Gastric Cancer* 2019, **22**(5):1044-1052.

12. Seyedin S, Wang PC, Zhang Q, Lee P: Benefit of Adjuvant Chemoradiotherapy for Gastric Adenocarcinoma: A SEER Population Analysis. *Gastrointest Cancer Res* 2014, **7**(3-4):82-90.

13. Stump PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, Goodman KA, Rusthoven CG: Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. *Cancer* 2017.

14. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH et al: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol* 2012, **30**(3):268-273.

15. Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH et al: Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. *J Clin Oncol* 2015, **33**(28):3130-3136.

16. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001, **345**(10):725-730.

17. Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM et al: Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. *Lancet Oncol* 2018.

18. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven HW, Nieuwenhuijzen GA, Hopsers GA, Bonenkamp JJ et al: Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. *Lancet Oncol* 2015, **16**(9):1090-1098.

19. Wang X, Zhao DB, Yang L, Chi Y, Tang Y, Li N, Wang SL, Song YW, Liu YP, Liu WY et al: S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study. *Br J Cancer* 2018, **118**(3):338-343.

20. Wong RK, Jang R, Darling G: Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy. *J Gastrointest Oncol* 2015, **6**(1):89-107.

21. Barzi A, Yang D, Lenz HJ, Sadeghi S: Outcomes with adjuvant chemo-radiation (ACRT) in patients (pts) with localized gastric cancer (GC): Analysis of National Cancer Data Base (NCDB). *Journal of Clinical Oncology* 2016,
22. Saito H, Kono Y, Murakami Y, Kuroda H, Matsunaga T, Fukumoto Y, Tomohiro O, Fujiwara Y: Gross Appearance and Curability Are Predictive Factors of a Better Prognosis After Gastrectomy in Gastric Cancer Patients with Metastasis to the Adjacent Peritoneum of the Stomach. Yonago Acta Med 2017, 60(3):174-178.

23. Petrelli F, Trevisan F, Cabiddu M, Sgroi G, Bruschieri L, Rausa E, Ghidini M, Turati L: Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. Ann Surg 2020, 271(3):440-448.

Figures

Figure 1
Kaplan-Meier plots for disease-free survival (DFS) for entire cohort
Figure 2

Kaplan-Meier plots for disease-free survival (DFS) after PSM